160 related articles for article (PubMed ID: 11604470)
1. Rapamycin's resurrection: a new way to target the cancer cell cycle.
Garber K
J Natl Cancer Inst; 2001 Oct; 93(20):1517-9. PubMed ID: 11604470
[No Abstract] [Full Text] [Related]
2. Pten signaling in gliomas.
Knobbe CB; Merlo A; Reifenberger G
Neuro Oncol; 2002 Jul; 4(3):196-211. PubMed ID: 12084351
[TBL] [Abstract][Full Text] [Related]
3. Type 1 insulin-like growth factor regulates MT1-MMP synthesis and tumor invasion via PI 3-kinase/Akt signaling.
Zhang D; Brodt P
Oncogene; 2003 Feb; 22(7):974-82. PubMed ID: 12592384
[TBL] [Abstract][Full Text] [Related]
4. Enhanced sensitivity of multiple myeloma cells containing PTEN mutations to CCI-779.
Shi Y; Gera J; Hu L; Hsu JH; Bookstein R; Li W; Lichtenstein A
Cancer Res; 2002 Sep; 62(17):5027-34. PubMed ID: 12208757
[TBL] [Abstract][Full Text] [Related]
5. Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR.
Neshat MS; Mellinghoff IK; Tran C; Stiles B; Thomas G; Petersen R; Frost P; Gibbons JJ; Wu H; Sawyers CL
Proc Natl Acad Sci U S A; 2001 Aug; 98(18):10314-9. PubMed ID: 11504908
[TBL] [Abstract][Full Text] [Related]
6. Regulation of translation initiation by FRAP/mTOR.
Gingras AC; Raught B; Sonenberg N
Genes Dev; 2001 Apr; 15(7):807-26. PubMed ID: 11297505
[No Abstract] [Full Text] [Related]
7. The complexity of PTEN: mutation, marker and potential target for therapeutic intervention.
Steelman LS; Bertrand FE; McCubrey JA
Expert Opin Ther Targets; 2004 Dec; 8(6):537-50. PubMed ID: 15584861
[TBL] [Abstract][Full Text] [Related]
8. The PTEN tumor suppressor protein: an antagonist of phosphoinositide 3-kinase signaling.
Vazquez F; Sellers WR
Biochim Biophys Acta; 2000 Feb; 1470(1):M21-35. PubMed ID: 10656987
[No Abstract] [Full Text] [Related]
9. [PTEN expression in endometrial cancer and the prognosis].
Kanamori Y; Uegaki K; Kigawa J; Terakawa N
Nihon Rinsho; 2004 Oct; 62 Suppl 10():406-9. PubMed ID: 15535277
[No Abstract] [Full Text] [Related]
10. Effects of the mammalian target of rapamycin inhibitor CCI-779 used alone or with chemotherapy on human prostate cancer cells and xenografts.
Wu L; Birle DC; Tannock IF
Cancer Res; 2005 Apr; 65(7):2825-31. PubMed ID: 15805283
[TBL] [Abstract][Full Text] [Related]
11. Cyclin D1 and c-myc internal ribosome entry site (IRES)-dependent translation is regulated by AKT activity and enhanced by rapamycin through a p38 MAPK- and ERK-dependent pathway.
Shi Y; Sharma A; Wu H; Lichtenstein A; Gera J
J Biol Chem; 2005 Mar; 280(12):10964-73. PubMed ID: 15634685
[TBL] [Abstract][Full Text] [Related]
12. Clinical development of mammalian target of rapamycin inhibitors.
Dancey JE
Hematol Oncol Clin North Am; 2002 Oct; 16(5):1101-14. PubMed ID: 12512385
[TBL] [Abstract][Full Text] [Related]
13. Scientists hopeful as they uncover molecular clues to prostate cancer.
Vanchieri C
J Natl Cancer Inst; 2005 Feb; 97(3):168-9. PubMed ID: 15687357
[No Abstract] [Full Text] [Related]
14. mTor is required for hypertrophy of Pten-deficient neuronal soma in vivo.
Kwon CH; Zhu X; Zhang J; Baker SJ
Proc Natl Acad Sci U S A; 2003 Oct; 100(22):12923-8. PubMed ID: 14534328
[TBL] [Abstract][Full Text] [Related]
15. Phosphoinositide signaling in urological disease.
Theodorescu D
J Urol; 2003 Jun; 169(6):2394-6. PubMed ID: 12771804
[No Abstract] [Full Text] [Related]
16. PI3K/PTEN/AKT pathway. A critical mediator of oncogenic signaling.
Paez J; Sellers WR
Cancer Treat Res; 2003; 115():145-67. PubMed ID: 12613196
[No Abstract] [Full Text] [Related]
17. Inhibitors of mTOR reverse doxorubicin resistance conferred by PTEN status in prostate cancer cells.
Grünwald V; DeGraffenried L; Russel D; Friedrichs WE; Ray RB; Hidalgo M
Cancer Res; 2002 Nov; 62(21):6141-5. PubMed ID: 12414639
[TBL] [Abstract][Full Text] [Related]
18. The biology and clinical relevance of the PTEN tumor suppressor pathway.
Sansal I; Sellers WR
J Clin Oncol; 2004 Jul; 22(14):2954-63. PubMed ID: 15254063
[TBL] [Abstract][Full Text] [Related]
19. Pten, a protean tumor suppressor.
Mutter GL
Am J Pathol; 2001 Jun; 158(6):1895-8. PubMed ID: 11395362
[No Abstract] [Full Text] [Related]
20. PTEN suppresses breast cancer cell growth by phosphatase activity-dependent G1 arrest followed by cell death.
Weng LP; Smith WM; Dahia PL; Ziebold U; Gil E; Lees JA; Eng C
Cancer Res; 1999 Nov; 59(22):5808-14. PubMed ID: 10582703
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
